BioCatalystWatch
BNTXWorkspace / BNTX / OverviewCompany library
Price
Market cap
Next catalystExpected 2026Pumitamig plus obrixtamig — planned ES-SCLC study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

pumitamig (BNT327/BMS986545)

PD-L1 × VEGF-A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

pumitamig (BNT327/BMS986545)

PD-L1 × VEGF-A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

pumitamig (BNT327/BMS986545)

PD-L1 / VEGF-A

Upcoming / outlook

PD-L1 × VEGF-A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Pumitamig plus obrixtamig — planned ES-SCLC study

PD-L1 × VEGF-A

PreINDP1P3FilingApproved
Upcoming / outlook

gotistobart (BNT316/ONC-392)

CTLA-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

gotistobart (BNT316/ONC-392)

CTLA-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Pumitamig plus obrixtamig — planned ES-SCLC study

PD-L1 × VEGF-A

PreINDP1P3FilingApproved
Upcoming / outlook

pumitamig (BNT327/BMS986545)

PD-L1 × VEGF-A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

PD-L1 × VEGF-A

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

Patient-specific neoantigens

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

autogene cevumeran (BNT122, RO7198457)

Patient-specific neoantigens

PreINDP1P2P3FilingApproved

6 shared lung cancer antigens

PreINDP1P2P3FilingApproved

HER2; PD-L1 × VEGF-A combination partner

PreINDP1P2P3FilingApproved

Partner / License out

PRAME

PreINDP1P2P3FilingApproved

Approved / commercial

SARS-CoV-2 spike

PreINDP1P2P3FilingApproved

SARS-CoV-2 spike

Approved

PreINDP1P2P3FilingApproved

SARS-CoV-2 spike

Approved

PreINDP1P2P3FilingApproved

SARS-CoV-2 spike

Approved

PreINDP1P2P3FilingApproved

SARS-CoV-2 spike

Approved

PreINDP1P2P3FilingApproved

SARS-CoV-2 spike

Approved

PreINDP1P2P3FilingApproved

SARS-CoV-2 spike

Approved

PreINDP1P2P3FilingApproved

History / paused

Patient-specific neoantigens

PreINDP1P2P3FilingApproved
autogene cevumeran (BNT122, RO7198457)

Patient-specific neoantigens

PreINDP1P2P3FilingApproved

P. falciparum CSP

PreINDP1P2P3FilingApproved

CLDN6

PreINDP1P2P3FilingApproved

NY-ESO-1 × MAGE-A3 × Tyrosinase × TPTE

PreINDP1P2P3FilingApproved

PSA × PAP × 3 additional prostate cancer antigens

PreINDP1P2P3FilingApproved

Selected TNBC antigens

PreINDP1P2P3FilingApproved

Selected ovarian cancer antigens

PreINDP1P2P3FilingApproved

Patient-specific neoantigens

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

BNTX PR & News

PR & News

BNTX SEC archive